- Home
- SKT vs RLAY Comparison
SKT vs RLAY Comparison
Compare SKT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | RLAY |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKT | RLAY |
|---|---|---|
| Price | $34.82 | $17.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $37.17 | $19.50 |
| AVG Volume (30 Days) | 614.7K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $3.90 | $324.03 |
| P/E Ratio | $66.08 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $31.13 | $5.01 |
| 52 Week High | $42.53 | $21.27 |
Technical Indicators
Market Signals| Indicator | SKT | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 16.66 | 38.54 |
| Support Level | $33.65 | $11.68 |
| Resistance Level | $34.96 | $20.29 |
| Average True Range (ATR) | 0.61 | 0.85 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 7.12 | 13.77 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.